Development of a placebo effect model combined with a dropout model for bipolar disorder

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 40, Issue 3, 2013, Pages 359-368

  Sun, Wan ^a   Laughren, Thomas P ^a   Zhu, Hao ^a   Hochhaus, Guenther ^b   Wang, Yaning ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Bipolar disorder; Clinical trial simulation; Dropout; Placebo model

Indexed keywords

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PLACEBO EFFECT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL DISTRIBUTION; SURVIVAL TIME; TREATMENT DURATION; YOUNG MANIA RATING SCALE;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DATABASES, FACTUAL; HUMANS; MODELS, PSYCHOLOGICAL; MONTE CARLO METHOD; PATIENT DROPOUTS; PLACEBO EFFECT; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84878754457     PISSN: 1567567X     EISSN: 15738744     Source Type: Journal    
DOI: 10.1007/s10928-013-9305-5     Document Type: Article

References (31)

1. Swann AC (2006) What is bipolar disorder? Am J Psychiatry 163(2):177-179
2. Angst J (2006) Do many patients with depression suffer from bipolar disorder? Canadian journal of psychiatry Revue canadienne de psychiatrie 51(1):3-5
3. Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429-435
4. Pilla Reddy V, Kozielska M, Johnson M, Vermeulen A, de Greef R, Liu J, Groothuis GM, Danhof M, Proost JH (2011) Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders. Clin Pharmacokinet 50(7):429-450. doi: 10.2165/11590590-000000000-00000
5. Kimko HC, Reele SS, Holford NH, Peck CC (2000) Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 68(5):568-577
6. Friberg LE, de Greef R, Kerbusch T, Karlsson MO (2009) Modeling and simulation of the time course of asenapine exposure response and dropout patterns in acute schizophrenia. Clin Pharmacol Ther 86(1):84-91
7. Shang EY, Gibbs MA, Landen JW, Krams M, Russell T, Denman NG, Mould DR (2009) Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder. J Pharmacokinet Pharmacodyn 36(1):63-80
8. Holford NH, Peace KE (1992) Results and validation of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA 89(23):11471-11475
9. Bhattaram VA, Siddiqui O, Kapcala LP, Gobburu JV (2009) Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease. AAPS J 11(3):456-464
10. Panel on Handing Missing Data in Clinical Trials, National Research Council (2010) The prevention and treatment of missing data in clinical trials. The National Academies Press, Washington, DC
11. Gomeni R, Lavergne A, Merlo-Pich E (2009) Modelling placebo response in depression trials using a longitudinal model with informative dropout. Eur J pharm Sci 36(1):4-10. doi: 10.1016/j.ejps.2008.10.025
12. Dutta S, Diderichsen P, Liu W (2011) Clinical trial simulation of outcome after accounting for high dropout typical of acute pain studies. Paper presented at the American College of Clinical Pharmacology 40th Annual Meeting, Chicago
13. Hu C, Sale ME (2003) A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 30(1):83-103
14. William-Faltaos D, Chen Y, Wang Y, Gobburu J, Zhu H (2012) Quantification of disease progression and dropout for Alzheimer's disease. Int J Clin Pharmacol Ther. doi: 10.5414/CP201787
15. U.S. Food and Drug Administration (2009) The critical path initiative: transforming the way FDA-regulated products are developed, evaluated, manufactured, and used
16. Gobburu JV, Lesko LJ (2009) Quantitative disease, drug, and trial models. Annu Rev Pharmacol Toxicol 49:291-301. doi: 10.1146/annurev.pharmtox.011008. 145613
17. Hutmacher MM, French JL, Krishnaswami S, Menon S (2011) Estimating transformations for repeated measures modeling of continuous bounded outcome data. Stat Med. doi: 10.1002/sim.4155
18. Hu C, Yeilding N, Davis HM, Zhou H (2011) Bounded outcome score modeling: application to treating psoriasis with ustekinumab. J Pharmacokinet Pharmacodyn 38(4):497-517. doi: 10.1007/s10928-011-9205-5
19. Benedetti F (2008) Mechanisms of placebo and placebo-related effects across diseases and treatments. Annu Rev Pharmacol Toxicol 48:33-60. doi: 10.1146/annurev.pharmtox.48.113006.094711
20. Gomeni R, Merlo-Pich E (2007) Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. Br J Clin Pharmacol 63(5):595-613. doi: 10.1111/j.1365-2125.2006.02815.x
21. Wang Y, Sung C, Dartois C, Ramchandani R, Booth BP, Rock E, Gobburu J (2009) Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development. Clin Pharmacol Ther 86(2):167-174
22. Dansirikul C, Silber HE, Karlsson MO (2008) Approaches to handling pharmacodynamic baseline responses. J Pharmacokinet Pharmacodyn 35(3):269-283. doi: 10.1007/s10928-008-9088-2
23. Lipkovich IA, Houston JP, Ahl J (2008) Identifying patterns in treatment response profiles in acute bipolar mania: a cluster analysis approach. BMC Psychiatry 8:65
24. Hall KT, Lembo AJ, Kirsch I, Ziogas DC, Douaiher J, Jensen KB, Conboy LA, Kelley JM, Kokkotou E, Kaptchuk TJ (2012) Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome. PLoS One 7(10):e48135. doi: 10.1371/journal.pone.0048135
25. Papakostas GI, Fava M (2009) Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol 19(1):34-40. doi: 10.1016/j.euroneuro.2008.08.009
26. Sinyor M, Levitt AJ, Cheung AH, Schaffer A, Kiss A, Dowlati Y, Lanctot KL (2010) Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin psychiatry 71(3):270-279. doi: 10.4088/JCP.08r04516blu
27. Diener HC, Dowson AJ, Ferrari M, Nappi G, Tfelt-Hansen P (1999) Unbalanced randomization influences placebo response: scientific versus ethical issues around the use of placebo in migraine trials. Cephalalgia 19(8):699-700
28. Mallinckrodt CH, Zhang L, Prucka WR, Millen BA (2010) Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull 43(1):53-72
29. Enck P, Klosterhalfen S, Weimer K, Horing B, Zipfel S (2011) The placebo response in clinical trials: more questions than answers. Philos Trans R Soc Lond B Biol Sci 366(1572):1889-1895. doi: 10.1098/rstb.2010.0384
30. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2011) Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications. J Clin Psychiatry 72(4):464-472. doi: 10.4088/JCP.10m06191
31. Khin NA, Chen YF, Yang Y, Yang P, Laughren TP (2012) Exploratory analyses of efficacy data from schizophrenia trials in support of new drug applications submitted to the US Food and Drug Administration. J Clin Psychiatry 73(6):856-864. doi: 10.4088/JCP.11r07539